Loading...

HCWB HCW BIOLOGICS INC Expansion Plans 8-K Filing

HCW

HCWB

HCW BIOLOGICS INC

(HCWB)

2025 8-K

Investor Agreement Details

License Agreement Update

Clinical Trial Update

Financial Results Released

Nasdaq Compliance Update

Payment Extension Update

Delisting Notice

Filing Amendment Notice

Equity Purchase Amendment

Financial Results

Rights Offerings

Voluntary Delisting

Rights Offerings

Management Changes

Asset Acquisitions

Equity Offerings

Rights Offerings

Equity Offerings

Financial Statements

Equity Offerings

Equity Agreement

Stock Split Approval

Financial Results

Agreement Amendment

Nasdaq Delisting Notice

Equity Purchase Agreement

Nasdaq Delisting Notice

Nasdaq Delisting Notice

Securities Agreement

License Agreement

Financial Results

Financial Results

Nasdaq Compliance Notice

Settlement Agreement and Re...

Delisting Notice

Annual Meeting of Stockholders

Financial Results Announcement

Criminal Fraud Event

Financial Results Announcement

Agreement for Stock Sale

Termination of Credit Agree...

Financial Results Announcement

Financial Results Announcement

Annual Meeting Results

Financial Results Announcement

Agreement for Line of Credit

Financial Results Announcement

External Links:

On November 18, 2025, HCW Biologics Inc. announced that the first patient was dosed in a Phase 1 clinical trial evaluating its lead product candidate, HCW9302, for an autoimmune disorder.

AI Assistant

HCW BIOLOGICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.